Accordingly, we generated (and patented—Section 6) a novel, specifically engineered, single chain, bispecific antibody in the form of a diabody (scDb-hERG1-β1) which has proven effective in targeting the hERG1/β1 integrin complex in cancer cells with high affinity [31]. Here, KCNH2 is linked to cancer.